Reports

Drug name	NICE TAs	Comments
Trametinib	TA396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Tranexamic acid injection		Hospital use only
Trastuzumab deruxtecan (Enhertu®)	TA704 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
Trastuzumab emtansine	TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Trastuzumab infusion	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer TA107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Funding approval should be sought prior to initiation
Treosulfan capsules		National CDF list
Treosulfan injection		For hospital use only
Tretinoin bleaching cream		Unlicensed special
Tretinoin capsules
Triamcinolone acetonide 0.1% w/w in OrabaseTM		Unlicensed special

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports